Loxo Oncology Inc. (NASDAQ:LOXO) shares fell 3.5% during mid-day trading on Friday . The stock traded as low as $24.52 and last traded at $24.88, with a volume of 61,381 shares traded. The stock had previously closed at $25.77.

Several research firms have issued reports on LOXO. Zacks Investment Research upgraded shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Thursday, May 5th. Cowen and Company restated a “buy” rating on shares of Loxo Oncology in a report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $29.60.

The company’s market capitalization is $539.00 million. The company has a 50 day moving average of $25.51 and a 200 day moving average of $23.75.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.14. On average, analysts expect that Loxo Oncology Inc. will post ($2.83) earnings per share for the current year.

In other news, Director Keith T. Flaherty sold 15,000 shares of the business’s stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $26.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now owns 60,482 shares of the company’s stock, valued at $1,572,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David P. Bonita sold 447,857 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $26.96, for a total value of $12,074,224.72. The disclosure for this sale can be found here.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.